Matthew McCourt

1.6k total citations
18 papers, 543 citations indexed

About

Matthew McCourt is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Matthew McCourt has authored 18 papers receiving a total of 543 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Immunology, 5 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Matthew McCourt's work include Monoclonal and Polyclonal Antibodies Research (4 papers), Immunotherapy and Immune Responses (3 papers) and Immune cells in cancer (3 papers). Matthew McCourt is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (4 papers), Immunotherapy and Immune Responses (3 papers) and Immune cells in cancer (3 papers). Matthew McCourt collaborates with scholars based in United Kingdom, United States and Australia. Matthew McCourt's co-authors include Elisabeth A. Bone, Peter de Nully Brown, Alan H. Davidson, W A Galloway, Andy J.H. Gearing, Annette Wright, Alan H. Drummond, Paul Beckett, Mark Whittaker and Wayne A. Border and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Cancer Research.

In The Last Decade

Matthew McCourt

16 papers receiving 518 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matthew McCourt United Kingdom 9 189 171 141 126 99 18 543
Adrian Zumsteg Switzerland 11 271 1.4× 287 1.7× 291 2.1× 89 0.7× 48 0.5× 14 803
Rob C. M. de Jong Netherlands 11 149 0.8× 287 1.7× 237 1.7× 136 1.1× 71 0.7× 22 583
Chul-Soo Cho South Korea 14 142 0.8× 278 1.6× 292 2.1× 90 0.7× 81 0.8× 15 816
Caroline Wallace United States 11 275 1.5× 237 1.4× 232 1.6× 79 0.6× 79 0.8× 13 628
Thomas Pap Switzerland 6 144 0.8× 246 1.4× 191 1.4× 74 0.6× 64 0.6× 7 689
Fumihiro Kimura Japan 12 84 0.4× 271 1.6× 92 0.7× 90 0.7× 113 1.1× 39 628
Behrouz Zand United States 12 350 1.9× 364 2.1× 204 1.4× 143 1.1× 83 0.8× 34 869
S Wade Ireland 12 99 0.5× 204 1.2× 230 1.6× 127 1.0× 114 1.2× 21 610
Julie Madden United Kingdom 9 212 1.1× 214 1.3× 110 0.8× 82 0.7× 33 0.3× 14 502
Tsutomu Seito Japan 11 194 1.0× 218 1.3× 110 0.8× 50 0.4× 42 0.4× 14 632

Countries citing papers authored by Matthew McCourt

Since Specialization
Citations

This map shows the geographic impact of Matthew McCourt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew McCourt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew McCourt more than expected).

Fields of papers citing papers by Matthew McCourt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew McCourt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew McCourt. The network helps show where Matthew McCourt may publish in the future.

Co-authorship network of co-authors of Matthew McCourt

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew McCourt. A scholar is included among the top collaborators of Matthew McCourt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew McCourt. Matthew McCourt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Zaleta, Alexandra K., Julie S. Olson, Fumiko Chino, et al.. (2025). Prior authorization: Patient involvement and time burden in cancer treatment.. JCO Oncology Practice. 21(10_suppl). 175–175.
2.
MacKenzie, Sasho, et al.. (2020). How Amateur Golfers Deliver Energy to the Driver. 8(1). 12640. 2 indexed citations
3.
4.
Sainson, Richard C.A., Matthew McCourt, Anil K. Thotakura, et al.. (2018). Abstract 2792: The combination of immune checkpoint blockers with the anti-ICOS KY1044 antibody results in a strong tumor response. Cancer Research. 78(13_Supplement). 2792–2792. 1 indexed citations
5.
Sainson, Richard C.A., et al.. (2018). Abstract LB-153: KY1055, a novel ICOS-PD-L1 bispecific antibody, efficiently enhances T cell activation and delivers a potent anti-tumour response in vivo. Cancer Research. 78(13_Supplement). LB–153. 4 indexed citations
6.
Cohen, E. Suzanne, Daniëlle M. Gerlag, Jamie I. D. Campbell, et al.. (2014). Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis. Annals of the Rheumatic Diseases. 74(10). 1924–1930. 60 indexed citations
7.
McCourt, Matthew, et al.. (2014). Taking care to take back. Social & Cultural Geography. 15(8). 983–985. 1 indexed citations
8.
Luheshi, Nadia, et al.. (2013). Abstract 1542: Th1 and Th2 cytokines determine how CD40 activation changes human macrophage function in vitro.. Cancer Research. 73(8_Supplement). 1542–1542. 1 indexed citations
9.
Eberlein, Cath, James Legg, Frank Gebhardt, et al.. (2013). Abstract 1616: Survivin regulates endothelial cell proliferation, survival and angiogenesis.. Cancer Research. 73(8_Supplement). 1616–1616. 1 indexed citations
10.
Luheshi, Nadia, Gareth Davies, Edmund Poon, et al.. (2013). Th1 cytokines are more effective than Th2 cytokines at licensing anti‐tumour functions in CD40‐activated human macrophages in vitro. European Journal of Immunology. 44(1). 162–172. 25 indexed citations
11.
Buchanan, Andrew, Steve Rust, Sridha Sridharan, et al.. (2012). Improved drug-like properties of therapeutic proteins by directed evolution. Protein Engineering Design and Selection. 25(10). 631–638. 13 indexed citations
12.
Cohen, E. Suzanne, Meina Liang, Inna Vainshtein, et al.. (2012). Protein engineering and preclinical development of a GM‐CSF receptor antibody for the treatment of rheumatoid arthritis. British Journal of Pharmacology. 168(1). 200–211. 22 indexed citations
13.
Stewart, Ross, Michelle Morrow, Matthieu Chodorge, et al.. (2011). Abstract LB-158: MEDI4736: Delivering effective blockade of immunosupression to enhance tumour rejection: Monoclonal antibody discovery and preclinical development. Cancer Research. 71(8_Supplement). LB–158. 7 indexed citations
14.
Grütter, Christian, Trevor Wilkinson, Richard V. Turner, et al.. (2008). A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions. Proceedings of the National Academy of Sciences. 105(51). 20251–20256. 43 indexed citations
15.
Yu, Ling, et al.. (2004). Combining TGF-β inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney International. 66(5). 1774–1784. 76 indexed citations
16.
Drummond, Alan H., Paul Beckett, Peter de Nully Brown, et al.. (1999). Preclinical and Clinical Studies of MMP Inhibitors in Cancer. Annals of the New York Academy of Sciences. 878(1). 228–235. 181 indexed citations
17.
McCourt, Matthew. (1996). Acute renal failure in the newborn. Critical Care Nurse. 16(5). 84–94. 3 indexed citations
18.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Adrian Zumsteg Breakdown of academic impact, for papers by Rob C. M. de Jong Breakdown of academic impact, for papers by Chul-Soo Cho Breakdown of academic impact, for papers by Caroline Wallace Breakdown of academic impact, for papers by Thomas Pap Breakdown of academic impact, for papers by Fumihiro Kimura Breakdown of academic impact, for papers by Behrouz Zand Breakdown of academic impact, for papers by S Wade Breakdown of academic impact, for papers by Julie Madden Breakdown of academic impact, for papers by Tsutomu Seito
Rankless by CCL
2026